Neogen Corporation (NASDAQ:NEOG) saw its stock price plummet by 5.06% in Friday's trading session, following the release of its disappointing third-quarter 2025 financial results. The food safety and animal health company's shares have been under significant pressure, with this latest drop adding to a series of setbacks for investors.
The company reported a net loss of $11 million for Q3 2025, a stark 442% increase from the loss in the same quarter last year. Revenue also declined by 3.4% to $221 million, falling short of analyst expectations by 1.5%. Neogen's earnings per share deteriorated further to a loss of $0.05, missing analyst estimates by 200% and deepening from the $0.009 loss per share in Q3 2024.
This poor quarterly performance comes amid a broader downturn for Neogen, with the stock having lost a staggering 83% of its value over the past five years. The company's struggles are further highlighted by a 57% decline in share price over the past year alone, with a 31% drop recorded just in the past week. Investors are growing increasingly concerned about Neogen's ability to return to profitability, especially as the company faces challenges in both its top and bottom lines. As the market digests these results, the outlook for Neogen remains uncertain, with analysts forecasting modest revenue growth of 2.5% per annum over the next three years, significantly below the 7.8% growth projected for the US Medical Equipment industry as a whole.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。